MA40902B1 - Vaccins hpv16 thérapeutiques - Google Patents
Vaccins hpv16 thérapeutiquesInfo
- Publication number
- MA40902B1 MA40902B1 MA40902A MA40902A MA40902B1 MA 40902 B1 MA40902 B1 MA 40902B1 MA 40902 A MA40902 A MA 40902A MA 40902 A MA40902 A MA 40902A MA 40902 B1 MA40902 B1 MA 40902B1
- Authority
- MA
- Morocco
- Prior art keywords
- therapeutic
- vaccines
- hpv16 vaccines
- therapeutic hpv16
- nucleic acid
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
Abstract
L'invention concerne des constructions d' acides nucléiques et des polypeptides de concepteur pouvant être utilisés en tant que vaccins thérapeutiques contre hpv16.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14191660 | 2014-11-04 | ||
PCT/EP2015/075516 WO2016071306A1 (fr) | 2014-11-04 | 2015-11-03 | Vaccins thérapeutiques contre le vph16 |
EP15791556.2A EP3215187B1 (fr) | 2014-11-04 | 2015-11-03 | Vaccins hpv16 thérapeutiques |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40902A MA40902A (fr) | 2017-09-13 |
MA40902B1 true MA40902B1 (fr) | 2018-12-31 |
Family
ID=52020908
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046378A MA46378A (fr) | 2014-11-04 | 2015-11-03 | Vaccins hpv16 thérapeutiques |
MA40902A MA40902B1 (fr) | 2014-11-04 | 2015-11-03 | Vaccins hpv16 thérapeutiques |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046378A MA46378A (fr) | 2014-11-04 | 2015-11-03 | Vaccins hpv16 thérapeutiques |
Country Status (33)
Country | Link |
---|---|
US (4) | US9701721B2 (fr) |
EP (2) | EP3421046A1 (fr) |
JP (2) | JP6325751B2 (fr) |
KR (1) | KR20170083562A (fr) |
CN (1) | CN107075521B (fr) |
AR (1) | AR102527A1 (fr) |
AU (2) | AU2015341926B2 (fr) |
BR (1) | BR112017009177A2 (fr) |
CA (1) | CA2965562C (fr) |
CL (1) | CL2017001089A1 (fr) |
CO (1) | CO2017004838A2 (fr) |
CY (1) | CY1121377T1 (fr) |
DK (1) | DK3215187T3 (fr) |
EA (1) | EA035461B1 (fr) |
ES (1) | ES2697903T3 (fr) |
HR (1) | HRP20181895T1 (fr) |
HU (1) | HUE040440T2 (fr) |
IL (1) | IL251895B (fr) |
LT (1) | LT3215187T (fr) |
MA (2) | MA46378A (fr) |
MD (1) | MD3215187T2 (fr) |
MX (1) | MX2017005788A (fr) |
MY (1) | MY181175A (fr) |
NZ (1) | NZ730802A (fr) |
PL (1) | PL3215187T3 (fr) |
PT (1) | PT3215187T (fr) |
RS (1) | RS58080B1 (fr) |
SA (1) | SA517381457B1 (fr) |
SG (1) | SG11201702997YA (fr) |
SI (1) | SI3215187T1 (fr) |
TW (2) | TWI694147B (fr) |
WO (1) | WO2016071306A1 (fr) |
ZA (1) | ZA201703055B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA035461B1 (ru) | 2014-11-04 | 2020-06-19 | Янссен Вэксинс Энд Превеншн Б.В. | Терапевтические вакцины против hpv16 |
EA037295B1 (ru) | 2015-08-20 | 2021-03-05 | Янссен Вэксинс Энд Превеншн Б.В. | Терапевтические вакцины против hpv18 |
MX2018013340A (es) * | 2016-05-02 | 2019-08-21 | Janssen Vaccines & Prevention Bv | Combinaciones de vacunas terapeuticas para el vph. |
CN106632694B (zh) * | 2017-01-24 | 2021-02-12 | 南京益康生物医药有限公司 | 一种重组蛋白及药物组合物与应用 |
AU2018335252A1 (en) | 2017-09-23 | 2020-02-27 | Boehringer Ingelheim Vetmedica Gmbh | Paramyxoviridae expression system |
US20200399348A1 (en) * | 2018-02-20 | 2020-12-24 | Emory University | HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth |
US20210038709A1 (en) * | 2018-03-12 | 2021-02-11 | Sqz Biotechnologies Company | Methods for treating hpv-associated diseases |
WO2020016394A1 (fr) * | 2018-07-20 | 2020-01-23 | Janssen Vaccines & Prevention B.V. | Vecteur adénoviral recombinant exprimant un antigène zika à productivité améliorée |
CN108939064B (zh) * | 2018-08-06 | 2021-12-10 | 南京颂悦生物科技有限公司 | 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗 |
CN108992665B (zh) * | 2018-08-06 | 2021-11-19 | 南京颂悦生物科技有限公司 | 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗 |
JP2022523564A (ja) | 2019-03-04 | 2022-04-25 | アイオーカレンツ, インコーポレイテッド | 機械学習を使用するデータ圧縮および通信 |
MX2022002883A (es) | 2019-09-20 | 2022-03-25 | Transgene | Combinacion de un poxvirus que codifica para polipeptidos de virus de papiloma humano (vph) e interleucina 2 (il-2) con un anticuerpo anti ligando 1 de muerte programada (pd-l1). |
US20230277645A1 (en) * | 2020-04-02 | 2023-09-07 | Inovio Pharmaceuticals, Inc. | Compositions and methods for treating vulvar dysplasia |
WO2021209897A1 (fr) | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Vaccins à base de psma et de steap1 et leurs utilisations |
AU2021270777A1 (en) * | 2020-05-12 | 2022-11-10 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
KR20230125200A (ko) * | 2020-11-24 | 2023-08-29 | 마 무초우 조 | 인간 유두종 바이러스에 대한 dna 백신 및 이를 사용하는 방법 |
CA3235779A1 (fr) * | 2021-10-22 | 2023-04-27 | Jian Yan | Compositions et procedes de traitement d'une lesion intra-epitheliale squameuse de haut grade (hsil) anale |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
EP1548118A2 (fr) | 1994-06-10 | 2005-06-29 | Genvec, Inc. | Système de vecteurs adenoviraux complémentaires et lignées cellulaires correspondantes |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
ATE278794T1 (de) | 1995-06-15 | 2004-10-15 | Crucell Holland Bv | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (fr) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Lignees de cellules complements e1 de l'adenovirus |
WO1998039411A1 (fr) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Lignees cellulaires de complementation de la region e1 d'un adenovirus |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
NZ515582A (en) | 1999-05-17 | 2003-11-28 | Crucell Holland B | Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35 |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
CA2384987A1 (fr) * | 1999-09-16 | 2001-03-22 | Zycos Inc. | Acides nucleiques codant pour des polypeptides de polyepitopes |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
AU2002211490A1 (en) | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
CN100537773C (zh) | 2000-11-23 | 2009-09-09 | 巴法里安诺迪克有限公司 | 改良安卡拉痘苗病毒变体 |
WO2002088346A2 (fr) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | Systeme destine a l'expression inductible dans des cellules eucariotes |
ATE447037T1 (de) | 2002-04-25 | 2009-11-15 | Crucell Holland Bv | Mittel und verfahren zur herstellung von adenovirusvektoren |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
CA2552508A1 (fr) * | 2003-12-31 | 2005-09-29 | Pharmexa Inc. | Induction de reponses immunitaires cellulaires au papillomavirus humain utilisant des compositions peptidiques et d'acides nucleiques |
EP1718738A2 (fr) | 2004-02-23 | 2006-11-08 | Crucell Holland B.V. | Procedes de purification de virus |
MX2007004595A (es) | 2004-11-08 | 2007-08-15 | Chromagenics Bv | Seleccion de celulas hospederas que expresan proteinas en altas concentraciones. |
WO2007073513A2 (fr) | 2005-11-10 | 2007-06-28 | Genvec, Inc. | Procede de propagation de vecteurs adenoviraux codant pour des produits geniques inhibiteurs |
MY154956A (en) | 2006-02-28 | 2015-08-28 | Vaxart Inc | Chimeric adenoviral vectors |
WO2007104792A2 (fr) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci |
MX2009008118A (es) * | 2007-01-30 | 2009-10-13 | Transgene Sa | Polipeptido e2 del virus del papiloma usado para vacunacion. |
DE102008010954A1 (de) * | 2008-02-25 | 2009-08-27 | Cichon, Günter, Prof.Dr. | DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen |
DK2350268T3 (en) | 2008-11-03 | 2015-03-23 | Crucell Holland Bv | PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS |
GB0823497D0 (en) | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
KR101820980B1 (ko) | 2010-02-15 | 2018-01-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Ad 26 아데노바이러스 벡터를 제조하는 방법 |
US9000139B2 (en) * | 2010-08-13 | 2015-04-07 | Genexine, Inc. | Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer |
US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
EP2601968A1 (fr) * | 2011-12-06 | 2013-06-12 | Deutsches Krebsforschungszentrum | Acides polynucléiques dérivés du VPH pour thérapie |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
SG11201701506PA (en) | 2014-09-03 | 2017-03-30 | Bavarian Nordic As | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
EA035461B1 (ru) | 2014-11-04 | 2020-06-19 | Янссен Вэксинс Энд Превеншн Б.В. | Терапевтические вакцины против hpv16 |
EA037295B1 (ru) | 2015-08-20 | 2021-03-05 | Янссен Вэксинс Энд Превеншн Б.В. | Терапевтические вакцины против hpv18 |
MX2018013340A (es) * | 2016-05-02 | 2019-08-21 | Janssen Vaccines & Prevention Bv | Combinaciones de vacunas terapeuticas para el vph. |
-
2015
- 2015-11-03 EA EA201790976A patent/EA035461B1/ru not_active IP Right Cessation
- 2015-11-03 WO PCT/EP2015/075516 patent/WO2016071306A1/fr active Application Filing
- 2015-11-03 MX MX2017005788A patent/MX2017005788A/es unknown
- 2015-11-03 EP EP18182588.6A patent/EP3421046A1/fr active Pending
- 2015-11-03 MA MA046378A patent/MA46378A/fr unknown
- 2015-11-03 MA MA40902A patent/MA40902B1/fr unknown
- 2015-11-03 MD MDE20170071T patent/MD3215187T2/ro unknown
- 2015-11-03 AU AU2015341926A patent/AU2015341926B2/en active Active
- 2015-11-03 NZ NZ730802A patent/NZ730802A/en not_active IP Right Cessation
- 2015-11-03 SI SI201530481T patent/SI3215187T1/sl unknown
- 2015-11-03 CA CA2965562A patent/CA2965562C/fr active Active
- 2015-11-03 SG SG11201702997YA patent/SG11201702997YA/en unknown
- 2015-11-03 LT LTEP15791556.2T patent/LT3215187T/lt unknown
- 2015-11-03 HU HUE15791556A patent/HUE040440T2/hu unknown
- 2015-11-03 DK DK15791556.2T patent/DK3215187T3/en active
- 2015-11-03 RS RS20181369A patent/RS58080B1/sr unknown
- 2015-11-03 PT PT15791556T patent/PT3215187T/pt unknown
- 2015-11-03 PL PL15791556T patent/PL3215187T3/pl unknown
- 2015-11-03 ES ES15791556T patent/ES2697903T3/es active Active
- 2015-11-03 KR KR1020177014129A patent/KR20170083562A/ko active IP Right Grant
- 2015-11-03 CN CN201580060062.4A patent/CN107075521B/zh active Active
- 2015-11-03 EP EP15791556.2A patent/EP3215187B1/fr active Active
- 2015-11-03 BR BR112017009177-1A patent/BR112017009177A2/pt active Search and Examination
- 2015-11-03 JP JP2017523902A patent/JP6325751B2/ja active Active
- 2015-11-03 MY MYPI2017701524A patent/MY181175A/en unknown
- 2015-11-04 TW TW104136379A patent/TWI694147B/zh not_active IP Right Cessation
- 2015-11-04 TW TW109113009A patent/TWI731654B/zh not_active IP Right Cessation
- 2015-11-04 US US14/932,789 patent/US9701721B2/en active Active
- 2015-11-04 AR ARP150103569A patent/AR102527A1/es unknown
-
2017
- 2017-04-25 IL IL251895A patent/IL251895B/en active IP Right Grant
- 2017-05-02 CL CL2017001089A patent/CL2017001089A1/es unknown
- 2017-05-03 ZA ZA201703055A patent/ZA201703055B/en unknown
- 2017-05-03 SA SA517381457A patent/SA517381457B1/ar unknown
- 2017-05-15 CO CONC2017/0004838A patent/CO2017004838A2/es unknown
- 2017-05-22 US US15/601,278 patent/US10071151B2/en active Active
-
2018
- 2018-04-12 JP JP2018076758A patent/JP6606571B2/ja active Active
- 2018-08-08 US US16/058,411 patent/US10555996B2/en active Active
- 2018-11-14 HR HRP20181895TT patent/HRP20181895T1/hr unknown
- 2018-11-15 CY CY20181101210T patent/CY1121377T1/el unknown
- 2018-12-21 AU AU2018282463A patent/AU2018282463B2/en active Active
-
2020
- 2020-01-29 US US16/775,709 patent/US11040096B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40902B1 (fr) | Vaccins hpv16 thérapeutiques | |
PH12019501931A1 (en) | Anti-pdl1 antibody formulations | |
CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
BR112018003019A2 (pt) | vacinas terapêuticas contra hpv18 | |
CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
MA40938A (fr) | Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps | |
MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
EA201891317A3 (ru) | Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения | |
MA40579A (fr) | Anticorps anti-cll-1 et immunoconjugués | |
MX2019013670A (es) | Formulaciones de anticuerpos y proteinas. | |
BR112017005381A2 (pt) | composições que compreendem células recombinantes de bacillus e um inseticida. | |
MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
MX2016014306A (es) | Marcadores para terapia con lipoproteinas de alta densidad (hdl). | |
MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
MX2017004473A (es) | Formulaciones de betalactamasa y usos de las mismas. | |
MX2018016362A (es) | Formulaciones de anticuerpo anti-cd19. | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
MX2019004690A (es) | Constructos de anticuerpos. | |
MX2017003121A (es) | Formulaciones de anticuerpos. | |
CL2019002733A1 (es) | Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico. | |
MX2020012893A (es) | Formulaciones de proteinas. | |
MY190102A (en) | Tolerogenic dna vaccine | |
ZA201703467B (en) | Methods of treating ocular conditions | |
MX2016016612A (es) | Formulaciones estables de undecanoato de testosterona. | |
AU363801S (en) | Nail care instruments |